Abstract CT088: EVT801, a Novel Selective VEGFR-3 Inhibitor Targeting Tumor Angiogenesis, is Pursuing Dose Escalation Stage of Phase I First-in-human Study
Cancer Research(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined